Live feed
·
INSIDERFilingvia Quantisnow
Inhibikase Therapeutics Inc. logo

Inhibikase Therapeutics (IKT) director Aurentz received 108,176 Stock Option (Right to Buy)

ByQuantisnow·Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Insider transactions reported

Vincent Aurentz (director at Inhibikase Therapeutics Inc., IKT) reported that they received 108,176 Stock Option (Right to Buy) on Jun 30, 2025.

Reporting person
Aurentz Vincent

Options and other derivatives

Options and other derivative transactions
DateTypeSecuritySharesPriceValueHeld after
Jun 30, 2025Grant or award (A)Stock Option (Right to Buy)On 108,176 Common Stock1+108,176--108,176 direct

Holdings before and after

  • Stock Option (Right to Buy): 0 to 108,176 direct

Footnotes from the filing

  1. 1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Transaction codes in this filing

Grant or award:
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ

What did Aurentz report in this IKT Form 4?

Vincent Aurentz (director at Inhibikase Therapeutics Inc., IKT) reported that they received 108,176 Stock Option (Right to Buy) on Jun 30, 2025.

What does transaction code A mean on an SEC Form 4?

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

Historical context for IKT

Earlier insider filings at IKT

Quantisnow market dataNASDAQ
Inhibikase Therapeutics Inc. logo
IKT
Inhibikase Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2020
Get push alerts for IKT

Follow IKT and get a push notification the moment its next story breaks.

Full IKT profile on Quantisnow
Original source Picked up and delivered by Quantisnow in real time

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IKT (Inhibikase Therapeutics Inc.) and more on Quantisnow.